Phase I trial of OTS11101, an anti‐angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor

OTS11101 is a novel peptide vaccine that acts as an angiogenesis inhibitor by inducing cytotoxic T lymphocyte (CTL) cells that specifically target vascular endothelial cells expressing vascular endothelial growth factor (VEGF) receptor 1. We conducted a phase I study to evaluate the safety, tolerabi...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Sci
Main Authors: Hayashi, Hidetoshi, Kurata, Takayasu, Fujisaka, Yasuhito, Kawakami, Hisato, Tanaka, Kaoru, Okabe, Takafumi, Takeda, Masayuki, Satoh, Taroh, Yoshida, Koji, Tsunoda, Takuya, Arao, Tokuzo, Nishio, Kazuto, Nakagawa, Kazuhiko
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2012
Assuntos:
Original Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7657180/
https://ncbi.nlm.nih.gov/pubmed/23020774
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12034
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares